Amaran Keselamatan

Direktori | Umum | Sistem QUEST3+

Increase size

Reset to Default

Decrease size

Banner NPRA

We invite you to take a short survey to help us improve our safety-related information on the NPRA website.

Your feedback is important and will help us better serve you.

Please visit the survey link and share your thoughts.

Thank you for your participation!

Safety Alerts

To receive the latest issues of Safety Alerts, you may join the NPRA Safety Information Mailing List by completing the subscription form at https://forms.office.com/r/kQKikSVYdK

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

14Okt

[Updated] 17-Hydroxyprogesterone Caproate (17-OHPC): Cancellation of Product Registration and Product Recall

10Okt

Paracetamol and Fixed Drug Eruption (FDE): Upward Trend of Reports Involving Paediatric Patients

01Okt

Fluconazole: Updates on the Known Risk of Spontaneous Abortion During Pregnancy and Congenital Malformations in Children Exposed to Fluconazole in Utero

30Sep

Pseudoephedrine: Risk of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS)

02Sep

Safety Signal Alert: Mefenamic Acid-Associated Generalised Bullous Fixed Drug Eruption (GBFDE)

26Ogs

Progestogens (Cyproterone Acetate, Medroxyprogesterone Acetate, Chlormadinone): Risk of Meningioma

12Ogs

Azacitidine (Injectable Formulation): Risk of Cutaneous Vasculitis

22Jul

17-Hydroxyprogesterone Caproate (17-OHPC): Potential Cancer Risk in Offspring Exposed in Utero and Limited Efficacy Data

15Jul

Hydroxychloroquine: Risk of Sweet’s Syndrome (Acute Febrile Neutrophilic Dermatosis)

28Jun

Anti-Clusters of Differentiation 20 (CD20) Antibodies (Rituximab, Obinutuzumab, Ofatumumab, Ocrelizumab): Risk of Pyoderma Gangrenosum

29Mei

Amoxicillin: Risk of Aseptic Meningitis

28Mei

Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors (Dapagliflozin, Empagliflozin, Canagliflozin): Interaction with Lithium (for Therapeutic Use) Leading to Decreased Serum Lithium Concentration

06Mei

[Updated] Olmesartan: Risk of Autoimmune Hepatitis

30Apr

Proton Pump Inhibitors: Risk of Erectile Dysfunction

29Apr

Levetiracetam and Clobazam: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

18Apr

Hydrochlorothiazide: Risk of Acute Respiratory Distress Syndrome (ARDS)

17Apr

Ciprofloxacin, Moxifloxacin, Levofloxacin and Ofloxacin (Fluoroquinolones) for Systemic Use (Oral and Injection): Risk of Suicidal Behaviours

12Mac

Domperidone: Risk of Psychiatric Withdrawal Events When Used Off-Label for Lactation Stimulation

04Mac

[Updated] Metformin: Risk of Vitamin B12 Deficiency

19Feb

Statins (Atorvastatin, Rosuvastatin, Simvastatin): Interaction with Ticagrelor Leading to Increased Risk of Rhabdomyolysis

22Jan

Imatinib: Risk of Thrombotic Microangiopathy

19Jan

Rivastigmine: Risks of QT Prolongation and Torsade de Pointes

01Dis

Clomiphene: Risk of Serious Visual Disturbances Potentially Leading to Blindness

30Nov

Ibrutinib (IMBRUVICA®): Package Insert Updates to Dose Modifications for Adverse Reactions and to Special Warnings and Precautions for Use

29Nov

[Updated] Loperamide: Risk of Acute Pancreatitis

29Nov

[Updated] Topiramate: Neurodevelopmental Disorders in Children Exposed to Topiramate during Pregnancy

13Okt

Isotretinoin: Risk of Psychiatric Disorders and Sexual Dysfunction

05Sep

Cephalosporins: Risk of Seizures

23Ogs

Valaciclovir: Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

07Ogs

[Updated] Clindamycin (Systemic): Risk of Acute Kidney Injury

02Ogs

Third-Generation Aromatase Inhibitors (Anastrozole; Exemestane; Letrozole): Risk of Tendon Disorders

18Jul

Statins: Risk of Inducing or Aggravating Myasthenia Gravis

13Jun

Terlipressin (Glypressin®): Serious or Fatal Respiratory Failure and Sepsis/Septic Shock in Patients with Type 1 Hepatorenal Syndrome (Type 1 HRS)

03Mei

Griseofulvin: Risk of Severe Cutaneous Adverse Reactions (SCARs)

02Mei

Comirnaty Vaccine: Risk of Heavy Menstrual Bleeding

19Apr

Azacitidine: Risk of Differentiation Syndrome

11Apr

Off-Label Use of Diclofenac Suppositories to Treat Fever in Children: Potential Risk of Acute Necrotising Encephalopathy of Childhood (ANEC)

23Mac

[Updated] Pholcodine: Risk of Anaphylaxis to Neuromuscular Blocking Agents (NMBAs)

16Jan

Donepezil: Risk of QT Prolongation and Torsade de Pointes

20Dis

Pneumococcal Polysaccharide Vaccine (23-Valent): Extensive Swelling of Vaccinated Limb

09Dis

Sorafenib: Risk of Thrombotic Microangiopathy (TMA)

06Dis

Hydroxychloroquine and Chloroquine: Risk of Hepatic Impairment

02Nov

Methadone: Risk of Hypoglycaemia

01Nov

Piperacillin: Risk of Haemophagocytic Lymphohistiocytosis (HLH)

27Okt

Iodinated Contrast Media: Risk of Hypothyroidism (Particularly in Newborns and Young Children)

20Okt

Safety Updates on COVID-19 Vaccines: Risk of Tinnitus

19Okt

Labetalol: Risk of Nipple Pain and Raynaud's Phenomenon of the Nipple

17Okt

Sertraline: Risk of Microscopic Colitis

05Okt

Nirmatrelvir/ Ritonavir (PAXLOVID): Risk of Anaphylaxis and Hypersensitivity Reactions

29Sep

Brolucizumab (Pagenax®): Risk of Intraocular Inflammation, Including Retinal Vasculitis and/or Retinal Vascular Occlusion (Updated Recommendations to Minimise the Known Risks)

28Sep

Alectinib (Alecensa®): Risk of Haemolytic Anaemia (New Warning and Precaution and Dose Modification Guidance)

27Sep

Metformin: Risk of Vitamin B12 Deficiency

19Jul

Corticosteroids (Systemic): Risk of Pheochromocytoma Crisis

19Jul

Chloroquine and Hydroxychloroquine: Risk of Psychiatric Disorders

18Jul

Azathioprine: Risk of Erythema Nodosum

23Jun

Loperamide: Risk of Acute Pancreatitis

20Jun

Empagliflozin: Risk of Tubulointerstitial Nephritis

16Jun

Olmesartan: Risk of Autoimmune Hepatitis

13Jun

Mavenclad® (Cladribine): Risk of Serious Liver Injury and New Recommendations About Liver Function Monitoring

17Mei

Safety Updates on COVID-19 Vaccines: Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) / Thrombosis with Thrombocytopenia Syndrome (TTS)

06Mei

Warfarin: Risk of Anticoagulant-Related Nephropathy (ARN)

05Mei

Hydrochlorothiazide, Chlorthalidone, Indapamide and Acetazolamide: Risk of Choroidal Effusion, Acute Myopia & Acute Angle-Closure Glaucoma

06Apr

Betamethasone (Systemic): Risk of Pheochromocytoma Crisis

21Mac

Tenofovir Alafenamide: Risk of Renal Adverse Effects

03Jan

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis Patients: Risk of Major Adverse Cardiovascular Events (MACE) and Malignancies [Excluding Non-Melanoma Skin Cancer (NMSC)]

31Dis

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis Patients: Risk of Major Adverse Cardiovascular Events (MACE) and Malignancies [Excluding Non-Melanoma Skin Cancer (NMSC)]

31Dis

Clindamycin: Risk of Acute Renal Failure

30Dis

Sulfamethoxazole & Trimethoprim (Co-Trimoxazole): Risk of Acute Respiratory Distress Syndrome (ARDS)

14Dis

Decitabine: Risk of Differentiation Syndrome

29Nov

Anastrozole: Risk of Depression

12Okt

Bortezomib: Risk of Guillain-Barré Syndrome and Demyelinating Polyneuropathy

07Okt

Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Risk of Abnormal Uterine Bleeding

09Sep

Sacubitril/Valsartan: Risk of Psychiatric Events

29Jul

Mycophenolate Mofetil (MMF) and Myocophenolic Acid (MPA): Risk of De Novo Purine Synthesis Inhibitors-Associated Acute Inflammatory Syndrome

08Jul

Oseltamivir: Risk of Haemorrhages

22Apr

Antidepressants (citalopram; desvenlafaxine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine; vortioxetine): Risk of Postpartum Haemorrhage (PPH)

22Apr

Tecentriq® (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs)

20Apr

Vascular endothelial growth factor (VEGF) inhibitors for systemic use (except application on eyes): Risk of artery dissections and aneurysms

20Apr

Mirtazapine: Risks of (i) Amnesia and (ii) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

20Apr

Ceftriaxone: Risk of encephalopathy

17Feb

Safety Updates on COVID-19 Vaccine (Comirnaty®)

29Jan

Mesalazine and sulfasalazine: Nephrolithiasis

29Jan

Efavirenz (including combination products): Risk of late onset neurotoxicity

29Jan

Oseltamivir: Thrombocytopenia

29Jan

Clozapine: Risk of serious bowel complications caused by constipation

29Jan

Abiraterone: Risk of hypoglycaemia due to drug interaction

20Jan

Ondansetron: Information updates on risk of birth defects

20Jan

Alemtuzumab (Lemtrada®): Revised indication, additional contraindications and risk minimisation measures

20Jan

Tumour Necrosis Factor alpha (TNFα): Kaposi’s Sarcoma

14Dis

Esmya (ulipristal acetate 5 mg): Withdrawal of product registration

08Sep

Gilenya® (fingolimod): New contraindication in pregnant women and in women of childbearing potential who are not using effective contraception

27Ogs

Parenteral nutrition containing amino acids and/or lipids: Risk of toxic degradations of ingredients when exposed to light, which may lead to adverse outcomes in paediatric patients less than 2 years of age

25Ogs

Propofol: Risk of priapism

14Ogs

Plaquenil® (hydroxycholoroquine): Risk of QT prolongation and other drug-drug interactions in the context of COVID-19 management

06Ogs

Topiramate: Risk of uveitis

06Ogs

Insulin: Risk of cutaneous amyloidosis

23Jun

Reminder on the risk of oculogyric crisis with metoclopramide use

04Jun

Domperidone: Restriction of use in paediatric patients less than 12 years of age

28Mei

Proton pump inhibitors: Risk of microscopic colitis

28Mei

Gabapentin: Risk of dysphagia

12Mei

Rocuronium: Kounis syndrome

12Mei

Nintedanib: Ischaemic colitis

07Apr

Guselkumab: Risk of anaphylaxis

06Apr

Esmya (ulipristal acetate 5 mg): Product recall due to potential risk of liver injury

06Apr

Intravenous iron-containing products: Kounis syndrome

06Apr

Nivolumab: Reports of cytomegalovirus (CMV) infection or reactivation

06Apr

Kyprolis® (carfilzomib): (i) Risk of progressive multifocal leukoencephalopathy (PML); (ii) Risk of hepatitis B virus (HBV) reactivation

06Apr

Esbriet® (pirfenidone): Drug-induced liver injury (DILI)

26Feb

Sulfasalazine: Interference with dihydronicotinamide-adenine dinucleotide/ dihydronicotinamide-adenine dinucleotide phosphate (NADH/NADPH) reaction assays

26Feb

Ondansetron: Birth defects

26Feb

Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors: Risk of severe lung inflammation

21Jan

New safety measure for sodium valproate: (i) Risk of congenital malformation in neonates and neurodevelopmental problems in children exposed to sodium valproate during pregnancy; (ii) Additional educational material for healthcare professionals and patients/caretakers

26Nov

Retinoids: Updated measures for pregnancy prevention during retinoids use

26Nov

FEBURIC® (febuxostat): Increased risk of cardiovascular death and all-cause mortality in patients treated with febuxostat in the CARES study

30Okt

Smecta® (dioctahedral smectite): Not recommended for use in children aged below 2 years and pregnant or breastfeeding women

03Sep

Clopidogrel: Interaction with boosted antiviral Human Immunodeficiency Virus (HIV) therapy leading to insufficient inhibition of platelet aggregation

03Sep

LEMTRADA® (alemtuzumab): (i) Risk of autoimmune hepatitis (ii) Other serious reactions temporally associated with alemtuzumab infusion (iii) Haemophagocytic lymphohistiocytosis

26Ogs

Diclofenac (systemic use): (i) Risk of anastomotic leakage and (ii) Risk of Kounis syndrome

26Ogs

Actemra® (tocilizumab): New important identified risk of hepatotoxicity

20Jun

Imovane® (zopiclone): New restriction of the indication and additional warnings on abuse and dependence

20Jun

TECENTRIQ® (atezolizumab): A new important identified risk – immune-related myositis

20Jun

Posaconazole: Pseudohyperaldosteronism

12Jun

Deferiprone: Risk of neurological disorders in children

12Jun

DARZALEX (daratumumab): New identified risk of Hepatitis B Virus reactivation

12Jun

Benlysta® (belimumab): Increased risk of serious psychiatric events

09Apr

Carbimazole and methimazole (thiamazole): (i) Risk of birth defects and neonatal disorders in case of exposure during pregnancy; (ii) Risk of pancreatitis

04Apr

Oral retinoids: Risk of neuropsychiatric symptoms

04Apr

Tapentadol: Risk of seizures and reports of serotonin syndrome when co-administered with other drugs

15Mac

Xylometazoline: Increased risk of serious ventricular arrhythmia in patients with long QT syndrome

15Mac

Direct-Acting Antivirals (DAAVs) : Risk of hypoglycaemia in patients with diabetes

31Jan

Ceftriaxone: Disturbed consciousness, convulsions or involuntary movements

31Jan

Beta-Lactam antibiotics: Severe Cutaneous Adverse Reactions (SCARs)

31Jan

Lamotrigine: Risk of hemophagocytic lymphohistiocytosis (HLH)

31Jan

Acetazolamide: A new contraindication during pregnancy

31Jan

Fluoroquinolones: Risk of aortic aneurysm and dissection

31Jan

Epilim® (Sodium Valproate): Important new restrictions on use

26Okt

Succinylated gelatin (modified fluid gelatin): Possible cross-reactions involving the allergen galactose-alpha-1,3-galactose (Alpha-gal)

26Okt

Tivicay® (dolutegravir): Reports of neural tube defects

26Okt

Xgeva® (denosumab): Risk of new primary malignancy

26Okt

Eltrombopag: Risk of interference with bilirubin and creatinine test results

26Okt

Tecentriq® (atezolizumab): Risk of nephritis

26Okt

Esmya® (ulipristal acetate): New contraindication, restricted indication and liver function monitoring requirement

10Okt

Varenicline tartrate: Loss of consciousness

10Okt

Montelukast sodium: Update on neuropsychiatric adverse reactions – obsessive-compulsive symptoms

10Okt

Isoniazid: Risk of pancreatitis

10Okt

Saccharomyces boulardii: Risk of fungaemia

10Okt

Azithromycin, clarithromycin, erythromycin and roxithromycin: Risk of Severe Cutaneous Adverse Reactions (SCAR)

10Okt

Apixaban: Drug interaction between apixaban and Selective Serotonin Reuptake Inhibitors (SNRI) and/or Serotonin and Noradrenaline Reuptake Inhibitors (SNRI) leading to increased risk of bleeding

28Ogs

Iodinated Contrast Media: Risk of Severe Cutaneous Adverse Reactions (SCAR)

30Jul

Stilnox® 10 mg film-coated tablet (zolpidem): Restriction of indication

30Jul

Domperidone and clarithromycin: Drug interaction leading to increased risk of QT interval prolongation

30Jul

Noradrenaline: Stress cardiomyopathy

25Jun

Acetazolamide: Risk of Severe Cutaneous Adverse Reactions (SCARs)

25Jun

Carbocisteine and acetylcysteine: Anaphylactic/anaphylactoid reactions and Severe Cutaneous Adverse Reactions (SCARs)

25Jun

Efavirenz: Risk of QTc interval prolongation

16Jun

Drug interaction of oral contraceptives containing ethinylestradiol with the direct-acting antiviral combinations of paritaprevir, ritonavir and ombitasvir with or without dasabuvir

15Jun

Mesalazine: Risk of photosensitivity reactions

13Jun

Methotrexate: Pulmonary alveolar haemorrhage

12Jun

Pemetrexed: Risk of nephrogenic diabetes insipidus and renal tubular necrosis

11Jun

Amoxicillin-containing products: Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and strengthening the risk of Severe Cutaneous Adverse Reactions (SCARs)

10Jun

Propofol and sodium valproate: Risk of increased propofol blood level when co-administered with valproate

24Apr

Esmya® 5 mg tablets (ulipristal acetate): Women taking Esmya® for uterine fibroids to have regular liver tests while safety review is ongoing; do not initiate treatment in new patients or those who have completed a previous treatment course

23Mac

Doxycycline: Risk of Jarisch-Herxheimer reaction

23Mac

Gadolinium-based Contrast Agents: Suspension/restriction of use following evidence of gadolinium deposits in the brain after magnetic resonance imaging (MRI) body scans

23Mac

Intravenous (IV) fluids containing electrolytes and/or carbohydrates: Risk of hyponatraemia

23Mac

Levetiracetam and methotrexate: Risk of drug-drug interaction

22Feb

Ofev® (nintedanib): Information on severe liver injury and the need for regular monitoring of liver function associated with the use in patients with idiopathic pulmonary fibrosis (IPF)

29Dis

Xofigo® (radium-223 dichloride): Important Safety Information Update Regarding Increased Incidence of Deaths and Fractures in a Randomized Clinical Trial with Xofigo® used in Combination with Abiraterone Acetate and Prednisolone/ Prednisone

06Okt

Ribomustin® (bendamustine): Increased Mortality Observed When Used in Non-approved Combination Treatments or Outside the Approved Indications; Monitor for Opportunistic Infections and Hepatitis B Reactivation

06Okt

Xgeva® (denosumab): Risk of Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation

03Jul

Keytruda® (pembrolizumab): Risk of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

03Jul

Zelboraf® (vemurafenib): Important Drug Warning – Risk of Dupuytren’s Contracture and Plantar Fascial Fibromatosis

05Jun

Domide® (thalidomide): New important advice regarding viral reactivation and pulmonary hypertension

05Jun

Revlimid® (lenalidomide): New important advice regarding viral reactivation

11Apr

Madonna® (levonorgestrel): Levonorgestrel-containing emergency hormonal contraception ─ New advice on interactions with hepatic enzyme inducers and contraceptive efficacy

11Apr

Escapelle® & Postinor-2® (levonorgestrel): Levonorgestrel-containing emergency hormonal contraception ─ New advice for users of hepatic-enzyme inducers

28Feb

Pomalyst® (pomalidomide): New important advice- Hepatitis B Virus status to be established before initiating treatment with pomalidomide

30Dis

Zaltrap® (aflibercept): Information on the risk of osteonecrosis of the jaw

24Nov

Implanon NXT® (etonogestrel): Implants have been found rarely in the vasculature and lung. An update on possible risks and complications regarding insertion, localisation, removal and migration

24Nov

Invokana® (canagliflozin): Advice on the risk of lower limb amputation (primarily of the toe) during treatment with canagliflozin-containing medicines

24Ogs

Tarceva® (erlotinib): First-line maintenance indication now restricted to treatment of patients whose tumours harbour an EGFR-activating mutation

03Ogs

Adempas® (Riociguat): New Contraindication for Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias (PH-IIP)

08Jun

Locabiotal® Solution (fusafungine): Withdrawal of registration following European Medicines Agency’s benefit-risk assessment

08Jun

Glivec® (imatinib) & Tasigna® (nilotinib): Risk of Hepatitis B reactivation

08Jun

Xalkori® (crizotinib): Inclusion of a new warning regarding cardiac failure

08Jun

Viekirax® (ombitasvir/ paritaprevir/ ritonavir) with or without Exviera® (dasabuvir): Not recommended in Child-Pugh B Patients

08Jun

Xgeva® 120mg & Prolia® 60mg (denosumab): Clinically Significant Cases of Hypercalcaemia after Cessation of Treatment with Denosumab in Paediatric Patients

31Dis

Cellcept® (mycophenolate mofetil): Teratogenic risk – important new pregnancy prevention advice for women and men

04Sep

Forxiga® (dapagliflozin): Risk of Diabetic Ketoacidosis During Treatment With Sodium Glucose Co-transporter 2 (SGLT2)Inhibitor - Dapagliflozin

04Sep

Motilium® (domperidone): New recommendations to minimise cardiac risks

23Mac

Xgeva®120mg Solution for Injection (denosumab): Updated recommendations to minimise the risk of severe symptomatic hypocalcaemia (SSH) and osteonecrosis of the jaw (ONJ)

12Feb

Artrodar®50mg (diacerein): New restrictions of use to limit the risk of severe diarrhoea and effects on the liver

31Dis

Reminyl® (galantamine hydrobromide): New Warning: Serious skin reactions (Stevens Johnson Syndrome [SJS] and acute generalised exanthematous pustulosis [AGEP])

21Okt

Revatio® (sildenafil citrate): Safety Information regarding Revatio® tablets for the treatment of pulmonary arterial hypertension (PAH)

21Okt

Topamax® (topiramate): Updated Warnings and Precautions on Visual Field Defects

27Ogs

Protaxos® (strontium ranelate): New restricted indication and contraindications for use

27Ogs

Neupogen® (filgrastim) & Neulastim® (pegfilgrastim): Risk of capillary leak syndrome in patients with cancer (filgastrim & pegfilgastrim) and in healthy donors (filgastrim only)

19Ogs

Gran® (filgrastim) & Peglasta® (pegfilgrastim): Risk of capillary leak syndrome in patients with cancer (filgastrim & pegfilgastrim) and in healthy donors (filgastrim only)

15Jul

Vectibix® (panitumumab): Rare cases of Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported in patients treated with Vectibix®

15Jul

Mencevax ACWY™ (meningococcal vaccine): New antibody persistence data

15Jul

Ritalin and Ritalin LA® (methylphenidate hydrochloride): New warning on priapism in patients treated for Attention Deficit Hyperactivity Disorder (ADHD)

17Jun

Risperidone and Paliperidone: Risk of Intraoperative Floppy Iris Syndrome (IFIS) in Patients Undergoing Cataract Surgery

30Mei

Dilatrend® (carvedilol): Warning on Severe Adverse Cutaneous Reactions

20Mei

Combination Products containing Cyproterone Acetate 2mg and Ethinylestradiol 0.035mg: Restriction of Indication and Measures to Reduce Risk of Thromboembolism

30Apr

Tykerb® (Lapatinib): Comparative data have shown that lapatinib based regimens are less effective than trastuzumab based regimens for metastatic breast cancer in certain settings

30Apr

Concerta® (Methylphenidate hydrochloride): New warning on priapism in patients treated for Attention Deficit Hyperactivity Disorder (ADHD)

30Apr

Zofran® (Ondansetron): Dose-dependent QT interval prolongation – updated information on posology for intravenous (IV) use in the prevention of Chemotherapy-Induced Nausea And Vomiting (CINV)

30Apr

Erbitux® (Cetuximab): Importance of establishing wild type RAS status (exons 2,3,4 of KRAS and NRAS) before treatment in metastatic colorectal cancer (mCRC)

30Apr

Ultracet® Tablet (tramadol and paracetamol): Association with Serious Skin Reactions–Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

30Apr

Frisium® (clobazam): Update to include serious skin reactions in package insert for Malaysia

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

Phone: +603-7883 5400

More Links

Privacy & Policy

More Links

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

NPRA Product Status

NPRA Product Status

Site Last Modified

Last Modified: Jumaat 20 Disember 2024, 19:30:56.

Online Services

NPRA Support System

Online Public Engagement

Online Procurement Announcement